Patent · US Active

Combination therapy for proliferative disorders

US9216170B2 · kind B2 · utility

3Cited by

7References

13Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Brian Higgins · Dayton, US
Kenneth Kolinsky · Bloomingdale, US
Gwen Nichols · New York, US
Kathryn Packman · Newton, US
Fei Su · Wang'an Town, TW

Key dates

Filing date	Feb 5, 2013
Grant date	Dec 22, 2015
Priority date	—
Expiry date	Feb 5, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.